Recent 8-K filings for PPCB
Highest-materiality recent filing
Nasdaq notifies Propanc Biopharma of non-compliance with $1.00 minimum bid price rule
- Notice received Dec 31, 2025; bid price below $1.00 for 35 consecutive business days.
- Compliance deadline June 30, 2026; must close at $1.00+ for 10 consecutive days.
-
Nasdaq notifies Propanc Biopharma of non-compliance with $1.00 minimum bid price rule
Notice received Dec 31, 2025; bid price below $1.00 for 35 consecutive business days.
-
Propanc Biopharma closes $1.0M private placement of Series C Preferred Stock to Hexstone Capital
Hexstone purchased 100 Series C Preferred shares at $10,000 each plus a warrant for up to 9,900 additional shares; total cash $1,000,099.
-
Propanc Biopharma enters Series C Preferred Stock financing with Hexstone Capital
Issues 100 shares of Series C Preferred convertible at lesser of $5.00 fixed or 85% of lowest trading price over conversion period.
-
Propanc Biopharma prices $4M public offering, uplists to Nasdaq; appoints two independent directors
Raised $4M gross ($3.34M net) via public offering of 1M shares at $4.00/sh; underwriters have 45-day option for 150K more.
-
Principal $67,860 for net $58,000; matures Apr 16, 2026; 15% one-time interest.
-
Propanc Biopharma raises $108K in two convertible note financings in Feb 2025
$65,000 convertible note (purchase price $56,000) issued Feb 6; 15% flat interest, maturity Nov 30, 2025.
-
Propanc Biopharma raises $46,875 via convertible note at 35% discount and 8% interest
Principal amount $50,000; purchase price $46,875; net proceeds for working capital.
-
Propanc Biopharma raises $72,500 via convertible note with aggressive conversion terms
$77,500 convertible note issued to GS Capital Partners; net proceeds $72,500, 8% interest, matures Feb 2024.
-
Propanc Biopharma enters $5M equity line with Dutchess Capital at 85% discount
Up to $5M of common stock sales over 24 months; purchase price 85% of lowest trading price during 7-day pricing period.
-
Propanc Biopharma secures $65K convertible note and AU$230K loan; issues warrant for 15M shares
Entered securities purchase agreement with 1800 Diagonal Lending LLC for $65,000 convertible note at 8% interest, convertible at 65% of market price.
-
Propanc Biopharma defaults on $125K convertible note; enters $5M equity facility
Entered equity line facility for up to $5M over 36 months; shares sold at 80% of lowest VWAP.
-
Propanc Biopharma issues $53,750 convertible note to Red Road with 35% discount conversion
Principal $53,750, net proceeds $50,000 after $3,750 fees; maturity Oct 6, 2023; 8% interest.
-
Propanc Biopharma raises $203K via convertible notes with dilutive conversion terms
Entered convertible note agreements with GS Capital ($93K principal, net $88K after $5K OID) and ONE44 ($110K principal, net $100K after $10K OID).
Materiality & sentiment trend
Max materiality 0.75 · Median 0.45 · Most common event debt